| pubmed-article:3123558 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3123558 | lifeskim:mentions | umls-concept:C0021027 | lld:lifeskim |
| pubmed-article:3123558 | lifeskim:mentions | umls-concept:C0235914 | lld:lifeskim |
| pubmed-article:3123558 | lifeskim:mentions | umls-concept:C0445604 | lld:lifeskim |
| pubmed-article:3123558 | lifeskim:mentions | umls-concept:C1979963 | lld:lifeskim |
| pubmed-article:3123558 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:3123558 | lifeskim:mentions | umls-concept:C2003903 | lld:lifeskim |
| pubmed-article:3123558 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:3123558 | pubmed:dateCreated | 1988-3-15 | lld:pubmed |
| pubmed-article:3123558 | pubmed:abstractText | We have developed an enzyme-linked immunosorbent assay (ELISA) for autoantibody to Ro/SS-A antigen (anti-Ro/SS-A) in order to more fully characterize the autoimmune response that occurs to this antigen in patients with subacute cutaneous lupus erythematosus (SCLE). The microtiter plate-immobilized, biochemically purified Ro/SS-A antigen reacted with anti-Ro/SS-A antibody, but not with other closely related specificities (anti-La/SS-B, anti-SM, anti-U1-RNP) or normal sera. The optimal pH of antigen-antibody reaction in this ELISA was 7.2. The binding of sera containing anti-Ro/SS-A was inhibited 80% by preincubation with the same amount of Ro/SS-A antigen used for coating the plate. Although 11 of the 14 (79%) SCLE sera studied had precipitating anti-Ro/SS-A antibody by immunodiffusion, 13 (93%) sera had abnormally elevated IgG, IgA, or IgM ELISA binding levels. A good correlation between IgG anti-Ro/SS-A ELISA binding levels and immunodiffusion titers was observed (r - 0.8588, p less than or equal to 0.001) suggesting that IgG is the major anti-Ro/SS-A antibody class detected by double immunodiffusion, Sera with a combination of high rheumatoid factor levels (latex 3+ or higher) and high anti-Ro/SS-A titers (1:8 or higher in immunodiffusion) tended to give an abnormally high IgM anti-Ro/SS-A ELISA binding levels. After rheumatoid factor activity was removed by absorption with heat-aggregated human IgG, a 50% decrease in IgM anti-Ro/SS-A ELISA binding was noted. On the other hand, absorption of rheumatoid factor-negative sera that contained high IgM anti-Ro/SS-A binding activity did not significantly decrease ELISA binding levels. Prednisone and 6-azathioprine reduced the level of IgG anti-Ro/SS-A autoantibody in sera of treated SCLE patients by 50%. The IgG subclass profile of anti-Ro/SS-A autoantibody was analyzed by using mouse monoclonal antibodies specific for the 4 human IgG subclasses. Of anti-Ro/SS-A positive SCLE sera, 91% had predominantly IgG1 subclass autoantibody. The coexistence of IgM and IgG anti-Ro/SS-A autoantibody and the predominance of the IgG1 subclass is compatible with the possibility that this autoantibody response is under T-cell control. The predominance of IgG1 in the autoimmune response to Ro/SS-A antigen in SCLE patients is consistent with the hypothesis that antibody dependent cell mediated cytotoxicity could be an important immunologic effector mechanism in this disorder. | lld:pubmed |
| pubmed-article:3123558 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3123558 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3123558 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3123558 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3123558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3123558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3123558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3123558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3123558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3123558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3123558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3123558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3123558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3123558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3123558 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3123558 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:3123558 | pubmed:issn | 0022-202X | lld:pubmed |
| pubmed-article:3123558 | pubmed:author | pubmed-author:ReimerC BCB | lld:pubmed |
| pubmed-article:3123558 | pubmed:author | pubmed-author:LimaT GTG | lld:pubmed |
| pubmed-article:3123558 | pubmed:author | pubmed-author:SontheimerR... | lld:pubmed |
| pubmed-article:3123558 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3123558 | pubmed:volume | 90 | lld:pubmed |
| pubmed-article:3123558 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3123558 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3123558 | pubmed:pagination | 158-64 | lld:pubmed |
| pubmed-article:3123558 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:3123558 | pubmed:meshHeading | pubmed-meshheading:3123558-... | lld:pubmed |
| pubmed-article:3123558 | pubmed:meshHeading | pubmed-meshheading:3123558-... | lld:pubmed |
| pubmed-article:3123558 | pubmed:meshHeading | pubmed-meshheading:3123558-... | lld:pubmed |
| pubmed-article:3123558 | pubmed:meshHeading | pubmed-meshheading:3123558-... | lld:pubmed |
| pubmed-article:3123558 | pubmed:meshHeading | pubmed-meshheading:3123558-... | lld:pubmed |
| pubmed-article:3123558 | pubmed:meshHeading | pubmed-meshheading:3123558-... | lld:pubmed |
| pubmed-article:3123558 | pubmed:meshHeading | pubmed-meshheading:3123558-... | lld:pubmed |
| pubmed-article:3123558 | pubmed:meshHeading | pubmed-meshheading:3123558-... | lld:pubmed |
| pubmed-article:3123558 | pubmed:meshHeading | pubmed-meshheading:3123558-... | lld:pubmed |
| pubmed-article:3123558 | pubmed:meshHeading | pubmed-meshheading:3123558-... | lld:pubmed |
| pubmed-article:3123558 | pubmed:meshHeading | pubmed-meshheading:3123558-... | lld:pubmed |
| pubmed-article:3123558 | pubmed:meshHeading | pubmed-meshheading:3123558-... | lld:pubmed |
| pubmed-article:3123558 | pubmed:meshHeading | pubmed-meshheading:3123558-... | lld:pubmed |
| pubmed-article:3123558 | pubmed:meshHeading | pubmed-meshheading:3123558-... | lld:pubmed |
| pubmed-article:3123558 | pubmed:meshHeading | pubmed-meshheading:3123558-... | lld:pubmed |
| pubmed-article:3123558 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3123558 | pubmed:articleTitle | Immunoglobulin class and subclass profile of the Ro/SS-A autoantibody response. | lld:pubmed |
| pubmed-article:3123558 | pubmed:affiliation | Department of Dermatology, University of Texas Health Science Center, Dallas 75235. | lld:pubmed |
| pubmed-article:3123558 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3123558 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:3123558 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3123558 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3123558 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3123558 | lld:pubmed |
